An observational study in Upper GIT Symptoms, sponsored by AstraZeneca. Completed at 25 sites in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-31.
Sponsored by AstraZeneca · Observational
This is a prospective , epidemiological, multi-centre, phase IV study, approximately 5,000 patients who suffer with upper gastrointestinal tract symptoms. Each patient will be assessed for GERD with GerdQ Thai Version.
AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Primary care clinic
Exclusion Criteria:
Prevalence of gastroesophageal reflux disease (GERD) in patients presented with upper gastrointestinal tract symptoms
Response to various treatments for patients who have been diagnosed of GERD
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca